Prescribing information

 

Prescribing information

Tools and resources for healthcare professionals to support the use of Xolair in day‑to‑day practice.

With the exception of the video resources, these items are available in print format. To order printed materials, please contact your local key account manager.

Preview of self-administration guide
 

DOSING AND SELF-ADMINISTRATION RESOURCES

From dosing guidance for healthcare professionals to how-to videos for patients, these resources are designed to make the transition to administration at home as smooth as possible.

See more

mode of action video
 

MODE OF ACTION VIDEO

Watch the video to learn more about Xolair’s highly specific mode of action, which targets both phases of the asthmatic response.

Watch

patient forms
 

PATIENT FORMS

These forms are designed to help you identify patients that have SAA and may be suitable for treatment with Xolair, and to help you assess response.

View

 
 

Preview of competency checklist
 

ADMINISTRATION POSTER

This poster illustrates step-by-step instructions for healthcare professionals administering Xolair.

View

YOUR XOLAIR DIARY
 

YOUR XOLAIR DIARY

This booklet allows patients to track their symptoms in the first 16 weeks of treatment with Xolair, helping healthcare professionals assess the effectiveness of Xolair for that patient.

View

YOUR QUESTIONS ANSWERED
 

YOUR QUESTIONS ANSWERED

This booklet is for patients prescribed Xolair to help them understand more about SAA and what to expect from their treatment.

View

 

 

*Xolair provides clinically meaningful improvements in quality of life for patients with severe allergic asthma.1

Indication2: Xolair should only be considered for patients with convincing IgE (immunoglobulin E) mediated asthma. In adults and adolescents (12 years of age and older): Xolair is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1 <80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist. In children (6 to <12 years of age): Xolair is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.

FEV1, forced expiratory volume in 1 second; IgE, immunoglobulin E; SAA, severe allergic asthma.

References

  1. Braunstahl GJ et al. Resp Med 2013;107(8):1141–1151.
  2. Xolair® (omalizumab) Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | December 2020 | 101303
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]